2011至2022年间超过25000例中枢神经系统恶性肿瘤患者接受肿瘤电场治疗(TTFields)的全球上市后安全性监测
该研究基于2011年10月至2022年10月北美、欧洲、以色列和日本的常规上市后监测数据,纳入25898例接受TTFields治疗的中枢神经系统恶性肿瘤患者,分析不良事件(AE)并按年龄、性别和诊断分层。结果显示,全因AE发生于18798例(73%)患者,TTFields相关AE发生于14599例(56%)患者,最常见为阵列下皮肤反应(43%)、电感觉(刺痛;14%)和热感觉(温暖;12%);未报告TTFields相关全身性AE。作者认为TTFields耐受性良好,安全性特征在各亚组间保持一致,提示其广泛适用性。
要点
- 全因AE发生于73%(18798例)患者,TTFields相关AE发生于56%(14599例)患者。
- 最常见治疗相关AE为阵列下皮肤反应(43%)、电感觉(14%)和热感觉(12%)。
- 未报告TTFields相关全身性AE,安全性特征在年龄、性别和诊断亚组间保持一致。
核心结论
- 这项超过25000例患者的长期真实世界分析显示,TTFields在中枢神经系统恶性肿瘤患者中耐受性良好;大多数治疗相关AE为可管理的局部、非严重皮肤事件;TTFields治疗的安全性特征在各亚组(年龄、性别和诊断)间保持一致,提示其广泛适用性。
研究设计与样本
- 研究为全球上市后监测安全性分析,收集2011年10月至2022年10月北美、欧洲、以色列和日本患者的常规上市后活动安全性数据。
- 共纳入25898例接受TTFields治疗的中枢神经系统恶性肿瘤患者,AE按年龄、性别和诊断分层。
主要发现
- 患者诊断分布为:新诊断胶质母细胞瘤(ndGBM)68%、复发胶质母细胞瘤(rGBM)26%、间变性星形细胞瘤/少突胶质细胞瘤4%、其他中枢神经系统恶性肿瘤2%。
- 中位(范围)年龄为59(3-103)岁;66%患者为男性;69%患者为18-65岁,0.4%为<18岁,30%为>65岁。
- 全因AE发生于18798例(73%)患者,TTFields相关AE发生于14599例(56%)患者。
- 最常见治疗相关AE为阵列下皮肤反应(43%)、电感觉(刺痛;14%)和热感觉(温暖;12%)。
- 治疗相关皮肤反应在儿童组(39%)、成人组(42%)和老年组(45%)之间相当,在男性(41%)和女性(46%)之间相当;在各诊断亚组间相似(ndGBM 46%、rGBM 34%、间变性星形细胞瘤/少突胶质细胞瘤42%、其他40%);未报告TTFields相关全身性AE。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tumor Treating Fields (TTFields) are alternating electric fields that disrupt cancer cell processes. TTFields therapy is approved for recurrent glioblastoma (rGBM), and newly-diagnosed (nd) GBM (with concomitant temozolomide for ndGBM; US), and for grade IV glioma (EU). We present an updated global, post-marketing surveillance safety analysis of patients with CNS malignancies treated with TTFields therapy. METHODS: Safety data were collected from routine post-marketing activities for patients in North America, Europe, Israel, and Japan (October 2011-October 2022). Adverse events (AEs) were stratified by age, sex, and diagnosis. RESULTS: Overall, 25,898 patients were included (diagnoses: ndGBM [68%], rGBM [26%], anaplastic astrocytoma/oligodendroglioma [4%], other CNS malignancies [2%]). Median (range) age was 59 (3-103) years; 66% patients were male. Most (69%) patients were 18-65 years; 0.4% were < 18 years; 30% were > 65 years. All-cause and TTFields-related AEs occurred in 18,798 (73%) and 14,599 (56%) patients, respectively. Most common treatment-related AEs were beneath-array skin reactions (43%), electric sensation (tingling; 14%), and heat sensation (warmth; 12%). Treatment-related skin reactions were comparable in pediatric (39%), adult (42%), and elderly (45%) groups, and in males (41%) and females (46%); and similar across diagnostic subgroups (ndGBM, 46%; rGBM, 34%; anaplastic astrocytoma/oligodendroglioma, 42%; other, 40%). No TTFields-related systemic AEs were reported. CONCLUSIONS: This long-term, real-world analysis of > 25,000 patients demonstrated good tolerability of TTFields in patients with CNS malignancies. Most therapy-related AEs were manageable localized, non-serious skin events. The TTFields therapy safety profile remained consistent across subgroups (age, sex, and diagnosis), indicative of its broad applicability.
引用
- Mrugala MM, Shi W, Iwomoto F, et al. Global post‑marketing safety surveillance of Tumor Treating Fields (TTFields) therapy in over 25,000 patients with CNS malignancies treated between 2011-2022. J Neurooncol. 2024. PMID: 38949692. doi:10.1007/s11060-024-04682-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。